BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 225 filers reported holding BRIDGEBIO PHARMA INC in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,735,933 | +53.3% | 331,283 | 0.0% | 0.68% | +17.8% |
| Q2 2023 | $5,698,068 | +3.7% | 331,283 | 0.0% | 0.57% | +12.1% |
| Q1 2023 | $5,492,672 | +117.6% | 331,283 | 0.0% | 0.51% | +99.6% |
| Q4 2022 | $2,524,376 | -23.3% | 331,283 | 0.0% | 0.26% | +21.9% |
| Q3 2022 | $3,293,000 | +9.5% | 331,283 | 0.0% | 0.21% | +3.4% |
| Q2 2022 | $3,008,000 | -10.6% | 331,283 | 0.0% | 0.20% | +6.8% |
| Q1 2022 | $3,363,000 | -39.1% | 331,283 | 0.0% | 0.19% | -45.2% |
| Q4 2021 | $5,526,000 | -64.4% | 331,283 | 0.0% | 0.35% | -70.0% |
| Q3 2021 | $15,527,000 | -23.1% | 331,283 | 0.0% | 1.16% | -38.7% |
| Q2 2021 | $20,195,000 | -1.0% | 331,283 | 0.0% | 1.89% | +4.5% |
| Q1 2021 | $20,407,000 | – | 331,283 | – | 1.80% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
| Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
| Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
| Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
| M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
| VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
| BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
| Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
| SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |